| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a protected threonine derivative, H-Thr(tBu)-OtBu does not have a specific biological target. Its primary utility is as a chemical building block in organic synthesis, particularly in peptide chemistry. The compound serves as a protected threonine unit that can be incorporated into peptide chains while both the side-chain hydroxyl and carboxyl groups are protected from unwanted reactions. Threonine is an essential amino acid that plays important roles in protein structure and is a site for post-translational modifications, but in its protected form, the compound is not designed to interact with biological receptors or enzymes. Its value lies in its chemical properties as a synthetic intermediate, enabling the construction of complex peptides and pharmaceutical compounds.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
H-Thr(tBu)-OtBu does not exhibit pharmacological activity in vitro. As a protected amino acid derivative, it is a synthetic intermediate rather than a bioactive compound. In vitro studies using this compound focus on its chemical reactivity, such as its use in peptide bond formation reactions, rather than assessments of pharmacological activity. The compound may be used as a substrate in enzymatic assays to study the cleavage of tert-butyl protecting groups, but these are analytical applications rather than pharmacological assessments. The compound does not bind to receptors, inhibit enzymes, or produce cytotoxic effects in cell-based assays at concentrations typically used for synthesis. Its role in research is almost exclusively as a reagent for organic synthesis. |
| ln Vivo |
H-Thr(tBu)-OtBu is not a pharmacologically active compound and therefore does not have defined in vivo activity as a drug. When administered to animals, the compound would likely be metabolized to release threonine, which would then enter normal metabolic pathways. The tert-butyl groups may provide enhanced lipophilicity compared to free threonine, potentially improving membrane permeability and oral absorption. However, the compound is not used therapeutically, and its in vivo effects would be limited to those of the released threonine, which is an essential amino acid involved in protein synthesis and metabolism. Its primary value remains in synthetic chemistry.
|
| Enzyme Assay |
In vitro assays for H-Thr(tBu)-OtBu are primarily focused on its chemical properties and reactivity rather than biological activity. Standard protocols in peptide synthesis involve the use of this compound as a protected threonine building block for solid-phase or solution-phase peptide synthesis. The compound is typically dissolved in polar aprotic solvents such as DMF or DCM, and coupled to other amino acids using standard peptide coupling reagents such as HATU, HOBt, or DIC. The progress of the coupling reaction can be monitored by HPLC or TLC. Both tert-butyl groups can be selectively removed under acidic conditions (e.g., TFA), revealing the free hydroxyl and carboxyl groups for further functionalization or peptide chain elongation.
|
| Cell Assay |
In vitro cellular assays using H-Thr(tBu)-OtBu are not commonly performed because the compound lacks intrinsic biological activity. The compound is used exclusively in synthetic chemistry applications and is not designed for cell culture studies. Its use is confined to the laboratory, where it serves as a building block for the preparation of peptides and pharmaceutical compounds.
|
| Animal Protocol |
In vivo animal studies with H-Thr(tBu)-OtBu are not typically conducted, as the compound is a synthetic intermediate rather than a pharmacologically active agent. If used in vivo, the compound would be administered to animals to study the metabolism of protected amino acid derivatives or to deliver threonine in a protected form. However, such studies are rare, and the compound is generally used exclusively in synthetic chemistry applications. Its use is confined to the laboratory, where it serves as a building block for the preparation of peptides and pharmaceutical compounds.
|
| ADME/Pharmacokinetics |
H-Thr(tBu)-OtBu is not a drug candidate, and pharmacokinetic data are not available. As a protected amino acid derivative, it is designed for chemical synthesis rather than systemic administration. If administered in vivo, the compound would likely be rapidly metabolized by peptidases to release threonine, which would then enter normal metabolic pathways. The tert-butyl groups may be cleaved by enzymes or chemical hydrolysis. However, the compound's pharmacokinetic properties have not been characterized, and its use is confined to in vitro synthetic applications. The compound has a boiling point of 70°C/0.8mmHg and a density of 0.959.
|
| Toxicity/Toxicokinetics |
The compound is generally considered to have low toxicity, consistent with its use as a chemical reagent. It should be stored in a dark place at room temperature. Standard laboratory safety precautions, including the use of personal protective equipment, are recommended. It is not classified as a highly toxic substance, but appropriate safety measures should be followed. Inhalation, ingestion, or skin contact should be avoided.
|
| References | |
| Additional Infomation |
O-tert-Butyl-L-threonine tert-butyl ester (H-Thr(tBu)-OtBu, CAS 5854-78-4) is a protected threonine derivative used as a building block in peptide synthesis. Its chemical formula is C₁₂H₂₅NO₃ and molecular weight is 231.33. The compound appears as a colorless to clear liquid. It features both tert-butyl ether and tert-butyl ester protecting groups. It is intended for research use only and is not for human therapeutic applications. The compound is typically stored in a dark place at room temperature.
|
| Molecular Formula |
C5H12CLNO3
|
|---|---|
| Molecular Weight |
169.6067
|
| Exact Mass |
169.05
|
| CAS # |
39994-75-7
|
| Related CAS # |
(Rac)-H-Thr-OMe hydrochloride;2170123-34-7
|
| PubChem CID |
2734893
|
| Appearance |
White to light yellow solid powder
|
| Boiling Point |
274.4ºC at 760 mmHg
|
| Melting Point |
64 °C
|
| Flash Point |
119.8ºC
|
| LogP |
0.369
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
10
|
| Complexity |
104
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
Cl[H].O([H])[C@]([H])(C([H])([H])[H])[C@@]([H])(C(=O)OC([H])([H])[H])N([H])[H]
|
| InChi Key |
OZSJLLVVZFTDEY-HJXLNUONSA-N
|
| InChi Code |
InChI=1S/C5H11NO3.ClH/c1-3(7)4(6)5(8)9-2;/h3-4,7H,6H2,1-2H3;1H/t3-,4+;/m1./s1
|
| Chemical Name |
methyl (2S,3R)-2-amino-3-hydroxybutanoate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8959 mL | 29.4794 mL | 58.9588 mL | |
| 5 mM | 1.1792 mL | 5.8959 mL | 11.7918 mL | |
| 10 mM | 0.5896 mL | 2.9479 mL | 5.8959 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
